Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.50 |
| ▸ | CNR1 | P21554 | 4/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886186 | 1.00 | CNR2 (0.50) | CNR2CNR1NPY1RHTTNPY2R | |
| SCHEMBL2886188 | 1.00 | CNR2 (0.50) | CNR2CNR1NPY1RHTTNPY2R | |
| SCHEMBL13379193 | 1.00 | CNR2 (0.50) | CNR2CNR1NPY1RHTTNPY2R | |
| SCHEMBL2887594 | 0.84 | CNR2 (0.53) | CNR2CNR1NPY1RHTTNPY2R | |
| SCHEMBL2889667 | 0.84 | CNR2 (0.51) | CNR2CNR1NPY1RHTTNPY2R | |
| SCHEMBL2889668 | 0.84 | CNR2 (0.51) | CNR2CNR1NPY1RHTTNPY2R | |
| SCHEMBL2887592 | 0.84 | CNR2 (0.53) | CNR2CNR1NPY1RHTTNPY2R | |
| SCHEMBL13379192 | 0.84 | CNR2 (0.51) | CNR2CNR1NPY1RHTTNPY2R | |
| SCHEMBL2889666 | 0.84 | CNR2 (0.51) | CNR2CNR1NPY1RHTTNPY2R | |
| SCHEMBL13379190 | 0.84 | CNR2 (0.53) | CNR2CNR1NPY1RHTTNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099673-A1 | DECAHYDROQUINOLINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK SHARP & DOHME CORP. | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099673-A1 | DECAHYDROQUINOLINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885NPY1R 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.